Title: ImPrint immune signature in 10,000 early stage breast cancer patients from the real world FLEX database

Publication: SABCS 2022, Poster ID: PD9-08

Authors: Brufsky et al.


Using a real world database of 10 000 patients enrolled in the FLEX trial, which includes patients who are largely underrepresented in most clinical trials, we identified patients with immune sensitivity ImPrint.


  • In this study, most patients who are predicted to benefit from ICIs have MP High Risk or BP Basal Type tumors
  • 321 (5.0%) patients with HR+/HER 2 tumors were ImPrint
  • Similar frequencies of immune sensitivity were observed in FLEX as in I SPY 2 1 3 when comparing MP High Risk patients with clinically high risk characteristics
  • Younger women and patients of Black or Latin race/ethnicity who more often have more aggressive tumors 8 9 also have higher proportions of ImPrint tumors
  • This large, real world dataset enables the identification of populations who may benefit from immune therapy beyond those typically included in clinical trials and supports the testing of checkpoint inhibitors in the immune positive subtype
  • Here, we utilized FLEX to evaluate a clinically relevant genomic signature, which may be further optimized in the future by subtype and used to inform treatment decisions
  • This first look at immune sensitivity with ImPrint in the 10 000 patient FLEX database generates preliminary data and hypotheses that will be explored in future FLEX sub-studies and this analysis was only possible using the FLEX full genome data